David Arkowitz brings over 30 years of experience in finance, operations, business development, and commercial leadership within the life sciences and biotech sectors. He is currently the CFO of Alkeus Pharmaceuticals, a privately held late-stage biopharma company focused on preserving sight in individuals with retinal diseases. Before joining Alkeus, Mr. Arkowitz was EVP, CFO, and Head of Business Development at Seres Therapeutics. He also served as CFO at Flexion Therapeutics, which was acquired by Pacira Biosciences, and as COO and CFO of Visterra, acquired by Otsuka Pharmaceuticals. Earlier in his career, he held CFO roles at Mascoma, AMAG Pharmaceuticals and Idenix Pharmaceuticals, where he also contributed in various leadership capacities. Mr. Arkowitz spent over 13 years at Merck, where he was VP and Controller of the U.S. pharmaceutical business, Controller of the global R&D division, and CFO of Merck’s Canadian subsidiary. In addition to his executive roles, Mr. Arkowitz serves on the board of directors of Kineta and has previously been a board member of F-star Therapeutics, Yumanity Therapeutics, Spring Bank Pharmaceuticals, Proteostasis Therapeutics, Aegerion Pharmaceuticals, and ImpactRx.
Team